Samsung Group’s biotechnology arm rallied Tuesday as a Korea Exchange evaluation committee decided not to delist the unit’s shares after financial regulators concluded it violated accounting rules.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
